A raw figure: 705 MEPs in Strasbourg, zero legislative initiative power. This is the paradox of the European Parliament, this institutional giant that shapes the Union without ever wielding the pen of the legislator first.
The European Parliament stands as the stage for a permanent co-decision with the Council, but it never holds the pen for the first draft. It never proposes a legislative text. Its budgetary influence is shared, far from the grip exercised by the French National Assembly, which alone can initiate and amend the main lines of public finances. Meanwhile, the European Commission jealously retains the monopoly on legislative initiative. As a result, the amendments from MEPs remain subject to the Commission’s arbitration, limiting their actual impact.
See also : Blue butterfly: discover its deep meaning and symbol in love
In Paris, the National Assembly possesses a formidable weapon: it can bring down the government, a lever that simply does not exist in Strasbourg. MEPs, on the other hand, are content to engage with the Commission, without ever being able to sanction national governments. It is an institutional mechanism designed for collaboration, very far from the French model of direct political accountability.
The European Parliament vs. the National Assembly: what fundamental differences?
Discussions about the European Parliament reveal both the extent of its powers and the uniqueness of its functioning compared to the French National Assembly. In Brussels and Strasbourg, the rule is co-decision: each text is developed in a continuous confrontation with the Commission and the Council. In Paris, the National Assembly imposes itself as the nerve center of political life, where parliamentary sovereignty is played out.
See also : The Secrets of Lipsticks: Unsung Heroes and Cult Brands to Discover
In France, the multiplicity of institutions gives an impression of abundance: agencies, commissions, high councils, each with its own missions. The Ministry of Health chooses the members of the commissions, while the board of directors of Afssaps (now ANSM) oversees drug regulation. The European Union, on the other hand, operates in a collegial and transparent manner: the Commission sets the framework, the Parliament debates, amends, but can never initiate a text. The institutional balance serves as the backbone. In Paris, the National Assembly keeps control over the government; in Strasbourg, the Parliament merely validates the Commission, with no direct influence over national executives. These are two diametrically opposed political logics.
Drug regulation in France reveals a complex architecture, marked by the coexistence of multiple bodies and the ongoing search for independent expertise. At the European level, the European Medicines Agency (EMA) manages centralized authorizations, in dialogue with actors such as the Food and Drug Administration (FDA), the Haute Autorité de santé (HAS), and Afssaps.
To better understand the effects of these institutional differences, the news on L’Actu Dissidente provides precise analyses of the power dynamics that traverse politics, whether European or French.
Competences, powers, and limits: what the European Parliament can (and cannot) do
The European Parliament intrigues with the breadth of its files… and the number of locks that frame its action. Being an MEP in Strasbourg or Brussels means discussing, amending, sometimes slowing down major texts, but never taking the initiative for a new law. This privilege remains reserved for the European Commission, which proposes the texts submitted for debate. This division of roles draws clear boundaries between political impetus and parliamentary work.
In the field of medicine, the Parliament discusses, gives an opinion, but does not have the final say. The major orientations are set, but concrete decisions, authorizations, prices, reimbursements, fall under the purview of technical agencies such as the EMA, or national bodies like Afssaps or HAS. Several specialized commissions intervene, each with its own prerogatives, while the political sphere must contend with an omnipresent expertise. Transparency has become a norm, but the Parliament’s control power remains framed: it questions, monitors, recommends, without being able to directly determine the price of a drug or set reimbursement rates.
To navigate this, here are the main bodies involved in regulation:
- Marketing Authorization Commission (AMM): led by Afssaps, it brings together experts, sometimes funded by the pharmaceutical industry.
- Transparency Commission: orchestrated by HAS, it evaluates the medical interest of new products.
- Economic Committee for Health Products (CEPS): responsible for negotiating prices, without any oversight from the European Parliament.
Independence remains a daily struggle. Continuing medical education is largely funded by the industry, raising real questions about the system’s ability to ensure decisions free from any suspicion. The Formindep collective, for example, demands a clear status for experts and the creation of an independent authority to address regular criticisms regarding conflicts of interest in drug evaluation.
European decision-making process: how laws are made and what is the role of MEPs?
In the European Union, law-making is a multi-handed affair. The European Commission submits its proposals, then the European Parliament and the Council co-decide. MEPs, directly elected by citizens, cannot propose a text, but they have the power to amend, accept, or reject projects from the Commission. This mechanism imposes a strict distribution of responsibilities that leaves elected officials with a balancing power rather than a directing one.
Debates take shape in specialized commissions, health, environment, legal affairs…, where expert hearings, contributions from patient associations, and external opinions feed the reflection. External experts, whether academics, doctors, or pharmacists, participate in these hearings and write reports, while having to publicly declare their interests to avoid any suspicion of conflict.
Transparency is advancing, sometimes in small steps. Now, debates, votes, and declarations of interests are often accessible to the public. Patient associations, for their part, actively participate in pharmacovigilance by reporting adverse effects. The national pharmacovigilance commission examines these reports and can even recommend the withdrawal of a marketing authorization.
This institutional mesh, where institutions, experts, patients, and industry move forward together, shows the complexity of the European decision-making process. For each file, vigilance remains essential. Because behind every vote, public health, trust, and the autonomy of decisions are at stake, and the story continues to be written, under the watchful eye of all concerned actors.